Pneumonia最新文献

筛选
英文 中文
Streptococcus pneumoniae serotype distribution in Bangladeshi under-fives with community-acquired pneumonia pre-10-valent pneumococcal conjugate vaccination. 孟加拉国五岁以下儿童在接种 10 价肺炎球菌结合疫苗前患社区获得性肺炎的肺炎链球菌血清型分布。
IF 8.5
Pneumonia Pub Date : 2024-11-05 DOI: 10.1186/s41479-024-00152-w
Stefan M T Vestjens, Suzan P van Mens, Bob Meek, Tariq A Lalmahomed, Ben de Jong, Doli Goswami, Bart J M Vlaminckx, Dilruba Ahmed, Bartelt M de Jongh, Hubert P Endtz, W Abdullah Brooks, Ger T Rijkers
{"title":"Streptococcus pneumoniae serotype distribution in Bangladeshi under-fives with community-acquired pneumonia pre-10-valent pneumococcal conjugate vaccination.","authors":"Stefan M T Vestjens, Suzan P van Mens, Bob Meek, Tariq A Lalmahomed, Ben de Jong, Doli Goswami, Bart J M Vlaminckx, Dilruba Ahmed, Bartelt M de Jongh, Hubert P Endtz, W Abdullah Brooks, Ger T Rijkers","doi":"10.1186/s41479-024-00152-w","DOIUrl":"10.1186/s41479-024-00152-w","url":null,"abstract":"<p><strong>Background: </strong>Streptococcus pneumoniae is the most frequent causative pathogen of bacterial pneumonia in children worldwide. Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV10) in their national immunization program for infants in 2015. We assessed its potential coverage in under-fives with community-acquired pneumonia (CAP) in the years before PCV10 was introduced.</p><p><strong>Methods: </strong>A total of 1502 childhood pneumonia cases (< 5 year olds living in the urban section Kamalapur, Dhaka) were enrolled between 2011 and 2013. Acute phase and late (convalescent) serum samples were collected from 1380 cases. Serotype-specific pneumococcal antibody concentrations were measured using a 25-plex immunoassay panel. Pneumococcal CAP was diagnosed based on a serotype-specific pneumococcal antibody response.</p><p><strong>Results: </strong>S. pneumoniae was serologically identified as causative pathogen in 406/1380 (29%) cases. The five most prevalent serotypes were (in descending order) 11A, 22F, 3, 2 and 19F. Based on the percentage of pneumonia cases associated with PCV10 vaccine types, the potential PCV10 coverage was 29% (116/406).</p><p><strong>Conclusions: </strong>In almost a third of the studied cases S. pneumoniae was identified as a causative pathogen. Because of the characteristics of the immunoassay, this might well be a gross underestimation. Nevertheless, the potential PCV10-coverage was low. Given the high serotype diversity, the region might benefit greatly from a higher-coverage PCV or recombinant protein vaccine.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536696/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology, clinical and biological characteristics, and prognosis of critically ill COVID 19 patients: a single-center experience through 4 successive waves. COVID 19 重症患者的流行病学、临床和生物学特征及预后:一个中心连续 4 次的经验。
IF 8.5
Pneumonia Pub Date : 2024-11-05 DOI: 10.1186/s41479-024-00144-w
Sonia Tchakerian, Noémie Besnard, Vincent Brunot, Valérie Moulaire, Nacim Benchabane, Laura Platon, Delphine Daubin, Philippe Corne, Sonia Machado, Boris Jung, Eddine Bendiab, Liliane Landreau, Corrine Pelle, Romaric Larcher, Kada Klouche
{"title":"Epidemiology, clinical and biological characteristics, and prognosis of critically ill COVID 19 patients: a single-center experience through 4 successive waves.","authors":"Sonia Tchakerian, Noémie Besnard, Vincent Brunot, Valérie Moulaire, Nacim Benchabane, Laura Platon, Delphine Daubin, Philippe Corne, Sonia Machado, Boris Jung, Eddine Bendiab, Liliane Landreau, Corrine Pelle, Romaric Larcher, Kada Klouche","doi":"10.1186/s41479-024-00144-w","DOIUrl":"10.1186/s41479-024-00144-w","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to describe the characteristics of patients admitted to the intensive care unit with severe pneumonia due to SARS-CoV-2, comparing them according to successive waves, and to identify prognostic factors for morbidity and mortality.</p><p><strong>Materials and methods: </strong>This single-center retrospective observational descriptive study was conducted from March 10, 2020, to October 17, 2021. All adult patients admitted with SARS-CoV-2 pneumonia presenting acute respiratory failure were included. COVID 19 diagnosis was confirmed by RT-PCR testing of respiratory specimens. The primary endpoint was ICU mortality. Secondary endpoints were the occurrence of ventilator-associated pneumonia (VAP) or bronchopulmonary aspergillosis.</p><p><strong>Results: </strong>Over the study period, 437 patients were included of whom 282 (65%) patients were ventilated for 9 [5;20] days. Among the studied population, 38% were treated for one or more episodes of VAP, and 22 (5%) for bronchopulmonary aspergillosis. ICU mortality was 26% in the first wave, then fell and stabilized at around 10% in subsequent waves (p = 0.02). Increased age, Charlson index, SOFA score and lactatemia on admission were predictive of mortality. Survival at 90 days was 85% (95% CI 82-88) and was unaffected by the presence of VAP. However, the occurrence of bronchopulmonary aspergillosis increased mortality to 36%.</p><p><strong>Conclusion: </strong>In this study, we observed mortality in the lower range of those previously reported. Risk factors for mortality mainly included age and previous comorbidities. The prognosis of these critically ill Covid 19 patients improved over the four waves, underlining the likely beneficial effect of vaccination and dexamethasone.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seroprevalence and prognostic value of Aspergillus-specific IgG among non-neutropenic invasive pulmonary aspergillosis patients: a prospective multicenter study. 非中性败血症侵袭性肺曲霉菌病患者中曲霉菌特异性 IgG 的血清流行率和预后价值:一项前瞻性多中心研究。
IF 8.5
Pneumonia Pub Date : 2024-11-05 DOI: 10.1186/s41479-024-00154-8
Meng-Rui Lee, Hsu-Liang Chang, Yung-Hsuan Chen, Chia-Jung Liu, Li-Ta Keng, Hung-Ling Huang, Jann-Yuan Wang, Chau-Chyun Sheu, Inn-Wen Chong
{"title":"Seroprevalence and prognostic value of Aspergillus-specific IgG among non-neutropenic invasive pulmonary aspergillosis patients: a prospective multicenter study.","authors":"Meng-Rui Lee, Hsu-Liang Chang, Yung-Hsuan Chen, Chia-Jung Liu, Li-Ta Keng, Hung-Ling Huang, Jann-Yuan Wang, Chau-Chyun Sheu, Inn-Wen Chong","doi":"10.1186/s41479-024-00154-8","DOIUrl":"10.1186/s41479-024-00154-8","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the diagnostic and prognostic value of Aspergillus-specific IgG (Asp-IgG) for invasive pulmonary aspergillosis (IPA) in non-neutropenic non-hematologic patients.</p><p><strong>Methods: </strong>Between November 2019 and February 2022, we recruited 40 non-neutropenic, non-hematologic IPA patients from Taiwan and measured serum Asp-IgG levels using Phadia, Thermofisher. A positive Asp-IgG test was defined as a level > 40 mgA/L. We evaluated the association between Asp-IgG levels and overall survival, as well 90-day mortality rate of IPA patients.</p><p><strong>Results: </strong>Of the 40 participants, 11 (27.5%) tested positive for Asp-IgG, while 16 (40%) had positive galactomannan antigen (optical density > 1). Higher Asp-IgG levels were associated with improved overall survival (HR: 0.22, 95% CI: 0.05-0.99, p = 0.035) in multivariable Cox regression. The overall 90-day mortality rate was 65% (26/40). We found that patients with low Asp-IgG levels (≤ 40 mgA/L) had a borderline higher 90-day mortality rate compared to patients with high Asp-IgG levels (OR: 3.15, 95% CI: 0.75-13.28, p = 0.118). Stratifying by serum galactomannan and Aspergillus IgG levels, patients with elevated serum GM and low Asp-IgG had the highest 90-day mortality (80%, 8/10), followed by patients with low serum GM and low Asp-IgG (68.4%, 13/19).</p><p><strong>Conclusions: </strong>Asp-IgG was positive in approximately one-fourth of non-neutropenic IPA patients. Asp-IgG may hold potential as a clinical prognostic factor for IPA. Further studies are required to validate this finding.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical implications of persistently increased blood urea nitrogen/serum creatinine ratio (PI-BUN/Cr) in severe COVID-19 patients. 严重 COVID-19 患者血尿素氮/血清肌酐比值(PI-BUN/Cr)持续升高的临床意义。
IF 8.5
Pneumonia Pub Date : 2024-10-25 DOI: 10.1186/s41479-024-00140-0
Gustavo Casas Aparicio, Rosario Fernández Plata, Anjarath Higuera Iglesias, David Martínez Briseño, Rolando Claure-Del Granado, Manuel Castillejos Lopez, Joel Vázquez Pérez, Noé Alvarado Vásquez, Rafael Velázquez Cruz, Graciela Hernández Silva, Victor Ruiz, Ángel Camarena, Citlaltepetl Salinas Lara, Martha Tena Suck, Iñaki Montes de Oca Ambriz, Oswaldo Ortiz Toledo, Vianey Arvizu Serrano, Yared Almazan Chaparro, Edgar Flores-Soto, Luz María Torres Espíndola, Arnoldo Aquino-Gálvez, Victor Hugo Ahumada Topete
{"title":"Clinical implications of persistently increased blood urea nitrogen/serum creatinine ratio (PI-BUN/Cr) in severe COVID-19 patients.","authors":"Gustavo Casas Aparicio, Rosario Fernández Plata, Anjarath Higuera Iglesias, David Martínez Briseño, Rolando Claure-Del Granado, Manuel Castillejos Lopez, Joel Vázquez Pérez, Noé Alvarado Vásquez, Rafael Velázquez Cruz, Graciela Hernández Silva, Victor Ruiz, Ángel Camarena, Citlaltepetl Salinas Lara, Martha Tena Suck, Iñaki Montes de Oca Ambriz, Oswaldo Ortiz Toledo, Vianey Arvizu Serrano, Yared Almazan Chaparro, Edgar Flores-Soto, Luz María Torres Espíndola, Arnoldo Aquino-Gálvez, Victor Hugo Ahumada Topete","doi":"10.1186/s41479-024-00140-0","DOIUrl":"10.1186/s41479-024-00140-0","url":null,"abstract":"<p><strong>Background: </strong>Patients with COVID-19 may experience a persistent increase in the blood urea nitrogen over creatinine ratio (PI-BUN/Cr). Its elevation could reflect multiple underlying pathophysiological processes beyond prerenal injury but also warrants nuanced interpretation due to its complex interplay with various factors, underscoring the importance of investigating its effects on mortality and acute kidney injury in this population.</p><p><strong>Methods: </strong>We analized a retrospective and longitudinal cohort of patients admitted to a single center in Mexico City for patients with severe COVID-19. Between March 5, 2020 and August 25, 2021, we included patients with confirmed positive diagnosis for SARS-CoV-2, age > 18 years, disease severity was defined by clinical data of respiratory distress syndrome and a ratio of partial oxygen pressure to inspired oxygen fraction < 300 mmHg on admission. We excluded patients with End Stage Kidney Disease. Data was obtained from electronic medical records. PI-BUN/Cr was defined as an increase in the BUN/Cr ratio > 30 in more than 60% of measurements in the hospital. The outcomes included: risk factors to mortality and AKI in-hospital.</p><p><strong>Results: </strong>The cohort included 3,007 patients with a median age of 54.6 ± 14.5 years. 35% of patients died; 44.6% developed PI-BUN/Cr ratio and 71.4% AKI. Mortality was associated with older age > 60 years [Hazard ratio (HR)] = 1.45, 95% CI: 1.28-1.65; p < 0.001); male (HR 1.25, 95% CI 1.09-1.44; p = 0.002) and AKI (HR 3.29, 95% CI 2.42-4.46; p < 0.001); PI-BUN/CR & Non-AKI (HR = 2.82, 95% CI: 1.61-4.93; p < 0.001); Non PI-BUN/CR & AKI (HR = 5.47, 95% CI: 3.54-8.44; p < 0.001); and PI-BUN/CR & AKI (HR = 4.26, 95% CI: 2.75-6.62, p < 0.001). Only hiperuricemia was a risk factor for AKI (HR = 1.71, 95% CI: 1.30-2.25, p < 0.001).</p><p><strong>Conclusions: </strong>While PI-BUN/Cr alone may not directly associate with mortality, its capacity to sub-phenotype patients according to their AKI status holds significant promise in offering valuable insights into patient prognosis and outcomes. Understanding the nuanced relationship between PI-BUN/Cr and AKI enhances our comprehension of renal function dynamics. It equips healthcare providers with a refined tool for risk stratification and personalized patient management strategies.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11515407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of the Covid-19 pandemic on hospitalizations for non-Covid-19-pneumonia and exacerbations of chronic obstructive pulmonary diseases in Switzerland: comparison of national data between 2020/2021 and 2015-2019. Covid-19大流行对瑞士非Covid-19肺炎和慢性阻塞性肺病恶化住院治疗的影响:2020/2021年与2015-2019年全国数据比较。
IF 8.5
Pneumonia Pub Date : 2024-10-25 DOI: 10.1186/s41479-024-00150-y
Carla Bürke, Florent Baty, Frank Rassouli, Martin H Brutsche, Werner C Albrich
{"title":"Effect of the Covid-19 pandemic on hospitalizations for non-Covid-19-pneumonia and exacerbations of chronic obstructive pulmonary diseases in Switzerland: comparison of national data between 2020/2021 and 2015-2019.","authors":"Carla Bürke, Florent Baty, Frank Rassouli, Martin H Brutsche, Werner C Albrich","doi":"10.1186/s41479-024-00150-y","DOIUrl":"10.1186/s41479-024-00150-y","url":null,"abstract":"<p><strong>Background: </strong>Protective measures applied during the Covid-19 pandemic had a marked impact on the incidence of pneumonia. However, systematic data are lacking for hospitalizations for pneumonia and acute exacerbations of chronic obstructive lung diseases (AECOPD) not caused by SARS-CoV-2 in Switzerland. We aimed to compare the incidences of hospitalization for these entities between 2020/2021 and prepandemic years.</p><p><strong>Methods: </strong>This retrospective study examined all nationwide hospitalizations for non-Covid-19-pneumonia and AECOPD listed as primary diagnoses based on ICD-10 codes between 2015 and 2021 in a publicly available hospitalization database of the Swiss Federal Statistical Office. Hospitalizations for acute coronary syndrome (ACS) and stroke were used as controls. Changes of monthly incidences of hospitalizations, length of stay (LOS) and mortality were compared between 2020/2021 and the average of 2015-2019.</p><p><strong>Results: </strong>The incidences of hospitalizations for AECOPD and for pneumonia showed seasonal variations from 2015 to 2019 followed by significant and almost identical decreases in 2020/2021 (incidence rate ratio [IRR] 0.59, 95% CI: 0.45-0.77, p < 0.001, and IRR: 0.62, 95% CI: 0.52-0.74, p < 0.001, respectively). Hospital-mortality was slightly higher in 2020/2021 for AECOPD (2015-2019: 3.8%; 2020/2021: 4.2%, odds ratio [OR] 1.24, 95% CI: 1.07-1.44, p = 0.004) and for pneumonia (2015-2019: 4.5%, 2020/2021: 4.6%, odds ratio [OR] 1.17, 95% CI: 1.07-1.28, p < 0.001). Median LOS slightly decreased for AECOPD (2015-2019: 8 [IQR: 5-14] days; 2020/2021: 7 [IQR: 4-13] days, Wilcoxon test: p < 0.001) but slightly increased for pneumonia (2015-2019: 7 [IQR: 4-11] days; 2020/2021: 7 [IQR: 4-13] days, Wilcoxon test: p < 0.001). Throughout 2020/2021, there were no significant fluctuations observed in the incidences of ACS and stroke. (IRR: 0.98, 95% CI: 0.83-1.16, p = 0.810, IRR: 0.96, 95% CI: 0.81-1.14, p = 0.636, respectively).</p><p><strong>Conclusion: </strong>The first two years of the Covid-19 pandemic showed a marked decrease in incidences in AECOPD and non-Covid-19 pneumonia hospitalizations in Switzerland. It is likely that this effect is associated with the society-based, at first vigorous, social distancing measures.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11520113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142510053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine. 引入 13 价肺炎球菌结合疫苗后马拉维儿童经X光确诊的肺炎和相关的肺炎球菌携带。
IF 8.5
Pneumonia Pub Date : 2024-10-05 DOI: 10.1186/s41479-024-00147-7
Grace Mzumara, James Chirombo, Todd D Swarthout, Naor Bar-Zeev, Philliness Prisca Harawa, Mohamed Sanusi Jalloh, Amir Kirolos, Victoria Mukhula, Laura Newberry, Olawale Ogunlade, Richard Wachepa, Neil French, Robert S Heyderman, Pui-Ying Iroh Tam
{"title":"Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine.","authors":"Grace Mzumara, James Chirombo, Todd D Swarthout, Naor Bar-Zeev, Philliness Prisca Harawa, Mohamed Sanusi Jalloh, Amir Kirolos, Victoria Mukhula, Laura Newberry, Olawale Ogunlade, Richard Wachepa, Neil French, Robert S Heyderman, Pui-Ying Iroh Tam","doi":"10.1186/s41479-024-00147-7","DOIUrl":"10.1186/s41479-024-00147-7","url":null,"abstract":"<p><strong>Background: </strong>The 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced in Malawi in 2011 with an expected impact of reducing pneumococcal pneumonia in children. We aimed to describe clinical characteristics and nasopharyngeal (NP) carriage of pneumococcus by serotype in children hospitalized with primary end-point pneumonia (PEP) between 2013 and 19 after the introduction of PCV-13.</p><p><strong>Methods: </strong>We conducted a secondary analysis of children aged under-5-years hospitalized with acute respiratory illness (ARI) in Malawi. Chest radiographs conducted at admission were read by two independent clinicians according to WHO criteria for PEP, and a third reviewer resolved discordant diagnoses. NP swab specimens were processed and Streptococcus pneumoniae growth was serotyped. Multivariable regression analysis was conducted to assess the association between clinical characteristics, NP serotypes, and PEP.</p><p><strong>Results: </strong>We had complete radiographic and NP serotype data for 500 children, of which 54 isolates were vaccine-type (VT) (10.8%), 165 were non-VT (NVT; 33.0%), and 281 had no pneumococcal growth (56.2%). Among these, 176 (35.2%) had PEP on chest x-ray. Among those with PEP, pneumococcal carriage was documented in 43.8% of cases, and VT serotypes accounted for 10.8%. For children with PEP, we found no association between clinical characteristics and carrying either VT, NVT, or no pneumococcus.</p><p><strong>Conclusion: </strong>Carriage of S. pneumoniae remains high among children hospitalized with ARI in Malawi, but children with VT carriage were no more likely to have PEP than children carrying no pneumococcus or those with NVT carriage. There were no differences in clinical characteristics between those carrying VT, NVT, or no pneumococcus.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in China among children under 14 years of age post-implementation of the PCV13: a systematic review and meta-analysis (2017-2024). PCV13 实施后中国 14 岁以下儿童肺炎链球菌的血清型分布和抗菌药耐药性:系统综述和荟萃分析(2017-2024 年)。
IF 8.5
Pneumonia Pub Date : 2024-10-05 DOI: 10.1186/s41479-024-00141-z
Yue Li, Sijie Wang, Liang Hong, Lijing Xin, Fei Wang, Yibin Zhou
{"title":"Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae in China among children under 14 years of age post-implementation of the PCV13: a systematic review and meta-analysis (2017-2024).","authors":"Yue Li, Sijie Wang, Liang Hong, Lijing Xin, Fei Wang, Yibin Zhou","doi":"10.1186/s41479-024-00141-z","DOIUrl":"10.1186/s41479-024-00141-z","url":null,"abstract":"<p><strong>Background: </strong>Streptococcus pneumoniae (S. pneumoniae) is a major cause of morbidity and mortality in children worldwide, and its evolving serotype distribution and antibiotic resistance patterns are of global health concern. This meta-analysis aims to investigate the serotype distribution and antimicrobial resistance of S. pneumoniae after the introduction of pneumococcal conjugate vaccine 13-valent (PCV13) as a self-funded vaccine in Chinese pediatric populations.</p><p><strong>Methods: </strong>We systematically reviewed studies published between 2017 and 2024 that focused on S. pneumoniae serotypes isolated from children under 14 years old in mainland China. Data sources included PubMed, Embase, Web of Science, CNKI, Wanfang, and SinoMed. The findings were synthesized using either a fixed-effects or random-effects model.</p><p><strong>Results: </strong>Our meta-analysis included 12 studies, identifying the most common serotypes of S. pneumoniae were 19 F, 19 A, 23 F, 14, 6B and 6 A. Vaccine serotype coverage rates were 52.17% (95%CI: 44.91-59.42%) for PCV10, 74.77% (95%CI: 71.53-78.01%) for PCV13, 76.72% (95%CI: 75.37-78.07%) for PCV15 and 92.90% (95%CI: 92.09-93.71%) for PPSV23. Antimicrobial resistance was most pronounced for erythromycin at 93.73% (95%CI: 90.58-96.88%), followed by azithromycin, tetracycline, clindamycin, and sulfamethoxazole. Serotype prevalence and vaccine coverage varied regionally and by strain type.</p><p><strong>Conclusion: </strong>The distribution of S. pneumoniae serotypes and their antibiotic resistance profiles in children under 14 years in mainland China have remained relatively stable post-PCV13 introduction as a self-funded vaccine. The results support continued use and possible expansion of PCV13 immunization and highlight the importance of ongoing surveillance and vaccine development to cover all prevalent serotypes in China.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11453009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142376147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships between human serum albumin levels and septic shock, in-hospital, and out-of-hospital mortality in elderly patients with pneumonia in different BMI ranges. 不同体重指数范围的老年肺炎患者血清白蛋白水平与脓毒性休克、院内和院外死亡率之间的关系。
IF 8.5
Pneumonia Pub Date : 2024-09-25 DOI: 10.1186/s41479-024-00138-8
Sha Huang, Lanlan Chen, Ning Yang, Jiao Zhang, Yan Wang, Xiaoyan Chen
{"title":"Relationships between human serum albumin levels and septic shock, in-hospital, and out-of-hospital mortality in elderly patients with pneumonia in different BMI ranges.","authors":"Sha Huang, Lanlan Chen, Ning Yang, Jiao Zhang, Yan Wang, Xiaoyan Chen","doi":"10.1186/s41479-024-00138-8","DOIUrl":"https://doi.org/10.1186/s41479-024-00138-8","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective cohort identified the association of human serum albumin (HSA) with adverse outcomes (septic shock, in-hospital and out-of-hospital mortality) in elderly hospitalized patients who have community-acquired pneumonia (CAP) and specific body mass index (BMI).</p><p><strong>Materials and methods: </strong>This research included hospitalized CAP individuals (≥ 60 years) and was conducted at a teaching hospital in western China. All the patients were categorized into three populations based on two BMI cutoff values (18.5 kg/m<sup>2</sup> and 24 kg/m<sup>2</sup>). The data was acquired from medical records, local government mortality databases, and telephone interviews. Binomial logistic regression analysis was used to explore the associations between low HSA and septic shock and in-hospital mortality, and Cox regression analysis was used to explore the association between low HSA and out-of-hospital mortality.</p><p><strong>Results: </strong>A total of 627 patients were included in the analysis of in-hospital death and septic shock, and 431 patients were included in the analysis of out-of-hospital death. The study showed that 120 elderly patients with CAP (19.14%) died in the hospital, while 141 patients (32.71%) died out of the hospital, and 93 patients (14.83%) developed septic shock. No differences in in-hospital and out-of-hospital mortality were observed for BMI values < 18.5 kg/m<sup>2</sup> or BMI ≥ 24 kg/m<sup>2</sup>, regardless of whether HSA was ≥ 40 g/l or < 40 g/l. When 18.5 kg/m<sup>2</sup> ≤ BMI < 24 kg/m<sup>2</sup>, patients with HSA < 40 g/l had both higher in-hospital and out-of-hospital mortality compared with those with HSA ≥ 40 g/l (in-hospital death: 26.13% vs. 11.46%, p < 0.001; out-of-hospital death: 46.15% vs. 19.17%, p < 0.001). No significant differences were observed in the incidence of septic shock between patients with HSA < 40 g/l and those with HSA ≥ 40 g/l either in the overall population or when the BMI values were divided according to the cutoff values of 18.5 kg/m<sup>2</sup> and 24 kg/m<sup>2</sup>. After further logistic regression analysis and adjustment for potential confounders, the results showed that when 18.5 kg/m<sup>2</sup> ≤ BMI < 24 kg/m<sup>2</sup>, elderly CAP patients with HSA < 40 g/l had a higher risk of in-hospital and out-of-hospital mortality compared with those with HSA ≥ 40 g/l (in-hospital death: HR = 1.964, 95%CI = 1.08-3.573; out-of-hospital death: HR = 2.841, 95%CI = 1.745-4.627).</p><p><strong>Conclusions: </strong>HSA levels can predict the risk of in-hospital and out-of-hospital mortality in elderly patients with CAP and normal BMI values. However, HSA cannot predict the risk of septic shock in elderly patients hospitalized with CAP, irrespective of their BMI classification.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia. 病毒性社区获得性肺炎患者接受皮质类固醇治疗的效果。
IF 8.5
Pneumonia Pub Date : 2024-09-25 DOI: 10.1186/s41479-024-00146-8
Catia Cilloniz, Amedeo Guzzardella, Davide Calabretta, Albert Gabarrus, Maria Angeles Marcos, Antoni Torres
{"title":"Outcomes of corticosteroid therapy in patients with viral community-acquired pneumonia.","authors":"Catia Cilloniz, Amedeo Guzzardella, Davide Calabretta, Albert Gabarrus, Maria Angeles Marcos, Antoni Torres","doi":"10.1186/s41479-024-00146-8","DOIUrl":"https://doi.org/10.1186/s41479-024-00146-8","url":null,"abstract":"<p><strong>Aim: </strong>The objective of this study was to assess the therapeutic effects of corticosteroids in adult patients hospitalized with viral community-acquired pneumonia.</p><p><strong>Methods: </strong>This is a retrospective analysis of data collected prospectively from November 1996 to June 2024. All adult patients with viral community-acquired pneumonia were enrolled. The primary outcome was 30-day mortality. Secondary outcomes included all-cause in-hospital mortality, ICU admission, length of ICU and hospital stay, mechanical ventilation, and 1-year mortality. Propensity score matching (PSM) was used to obtain balance among the baseline variables in the two groups.</p><p><strong>Results: </strong>Of the 524 patients with viral pneumonia, 30 (6%) received corticosteroids and 494 (94%) did not. Patients were primarily male (n = 299, 57%), with a median [Q1-Q3] age of 66.9 [55-81] years. The 3:1 propensity matching procedure identified 90 patients not treated with corticosteroid (CS-) as controls. After PSM, no difference in 30-day mortality was found [7% (95%CI 1 to 22%) vs. 4% (95%CI 1 to 11%), p = 0.639]. The risk of death at 30 days did not differ significantly in unmatched and matched cohorts [Hazard Ratio (HR) 1.33 (0.32-5.63), p = 0.695 vs. HR 1.51 (0.28-8.27), p = 0.632, respectively]. Nor were differences found in hospital length of stay, ICU admission and length of stay, or mechanical ventilation requirement and duration between matched and unmatched CS + and CS-.</p><p><strong>Conclusions: </strong>There were no significant differences in the primary and secondary outcomes regarding the use of corticosteroids in patients with viral pneumonia.</p>","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11423511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142356068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A scientific manifesto for a new 5-year period: a new horizon for Pneumonia. 新五年的科学宣言:肺炎新地平线。
IF 8.5
Pneumonia Pub Date : 2024-09-05 DOI: 10.1186/s41479-024-00142-y
Giovanni Sotgiu
{"title":"A scientific manifesto for a new 5-year period: a new horizon for Pneumonia.","authors":"Giovanni Sotgiu","doi":"10.1186/s41479-024-00142-y","DOIUrl":"10.1186/s41479-024-00142-y","url":null,"abstract":"","PeriodicalId":45120,"journal":{"name":"Pneumonia","volume":null,"pages":null},"PeriodicalIF":8.5,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信